Qiming U.S. Healthcare Fund II, L.P. - 02 Aug 2021 Form 4 Insider Report for Icosavax, Inc.

Role
Former 10% Owner
Signature
/s/ Qiming U.S. Healthcare Fund II, L.P., by Qiming U.S. Healthcare GP II, LLC, its General Partner
Issuer symbol
N/A
Transactions as of
02 Aug 2021
Net transactions value
+$3,320,265
Form type
4
Filing time
02 Aug 2021, 21:27:12 UTC
Previous filing
28 Jul 2021
Next filing
01 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Conversion of derivative security $0 +3,310,228 $0.000000 3,310,228 02 Aug 2021 Direct F1, F2
transaction ICVX Common Stock Purchase $3,000,000 +200,000 +6% $15.00 3,510,228 02 Aug 2021 Direct F2, F5
transaction ICVX Common Stock Purchase $120,270 +8,018 +0.23% $15.00 3,518,246 02 Aug 2021 Direct F3
transaction ICVX Common Stock Purchase $199,995 +13,333 +0.38% $15.00 3,523,561 02 Aug 2021 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Series A-1 Preferred Stock Conversion of derivative security -12,480,498 -100% 0 02 Aug 2021 Common Stock 3,003,224 $0.000000 Direct F1, F2
transaction ICVX Series B-1 Preferred Stock Conversion of derivative security -1,275,817 -100% 0 02 Aug 2021 Common Stock 307,004 $0.000000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Qiming U.S. Healthcare Fund II, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's common stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, Qiming U.S. Healthcare Fund II, L.P. ("Qiming") is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.
F2 The securities are directly held by Qiming. Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the General Partner of Qiming. Gary Rieschel and Mark McDade are the managing members of Qiming GP. As a result, each of Qiming GP and Messrs. Rieschel and McDade may be deemed to beneficially own the shares held by Qiming.
F3 Shares reported herein as purchased on August 2, 2021 represent 8,018 shares of Common Stock purchased by Mark McDade.
F4 Shares reported herein as purchased on August 2, 2021 represent 13,333 shares of Common Stock purchased by Gary Rieschel.
F5 Shares reported herein as purchased on August 2, 2021 represent 200,000 shares of Common Stock purchased by Qiming.